To further assess this, it would be interesting to evaluate ST6GALNAC3 and ZNF660 promoter methylation also in cancer‐negative diagnostic biopsies, as promoter hypermethylation field effects in cancer‐negative diagnostic biopsies have previously been shown to predict the result of repeat biopsy (Moller et al., 2017; Partin et al., 2014; Stewart et al., 2013; Trock et al., 2012; Troyer et al., 2009; Van Neste et al., 2016). Here, ZNF660 is linked to cancer.